Chase C. Leavitt, General Counsel/Secretary at Lineage Cell Therapeutics, Inc. (LCTX), bought 5,000 shares at $1.02 ($5K) on 2019-08-13, disclosed to the SEC on 2019-08-15.
Open-market purchase of $5k LCTX by General Counsel/Secretary. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| ONCT | BUY | 2023-04-14 | $7K | — | Filing → |
| ONCT | BUY | 2022-01-31 | $23K | — | Filing → |
| ONCT | BUY | 2021-06-15 | $8K | — | Filing → |